Logo image
Back
Changes in Quality of Life in the First 5 Years of Disease in a Multicenter Cohort of Patients With Systemic Lupus Erythematosus
Journal article   Open access   Peer reviewed

Changes in Quality of Life in the First 5 Years of Disease in a Multicenter Cohort of Patients With Systemic Lupus Erythematosus

M. Urowitz, D. D. Gladman, D. Ibanez, J. Sanchez-Guerrero, S. C. Bae, C. Gordon, P. R. Fortin, A. Clarke, S. Bernatsky, J. G. Hanly, …
Arthritis care & research (2010), v 66(9), pp 1374-1379
01 Sep 2014
DOI: https://doi.org/10.1002/acr.22299
PMID: 24497416
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
http://hdl.handle.net/20.500.12648/8265View
Published, Version of Record (VoR)CC BY-NC-ND V4.0,  Open
url
https://doi.org/10.1002/acr.22299View
Published, Version of Record (VoR) Open

Abstract

Life Sciences & Biomedicine Rheumatology Science & Technology
Objective. The Medical Outcomes Study Short Form 36 (SF-36) is recommended to assess quality of life (QOL) in systemic lupus erythematosus (SLE). The aim of the current study was to assess QOL over time in the first 5 years of a multicenter inception cohort of patients with SLE. Methods. An inception SLE cohort was assembled according to a standardized protocol between 2000 and 2012. In addition to clinical and laboratory assessments, patients completed the SF-36 at yearly intervals. Only patients who had >= 5 completed QOL questionnaires were included in these analyses. Generalized estimating equation models were run separately for each of the 8 subscales and for the physical and mental component summary scores, adjusting for repeated measures by patients. Results. A total of 495 patients were included. The mean +/- SD disease duration at the first visit was 5.3 +/- 4.1 months. The mean +/- SD age at enrollment was 35.8 +/- 13.2 years. All 8 subscales and the 2 summary scores showed improvement in the first 2 years from enrollment. Between years 2 and 5, none of the subscales or summary scores showed any change. Minimum clinically important improvement was achieved by 35-56% of the patients and was influenced by demographic and disease factors. Conclusion. Unlike late-stage lupus, where QOL is stable over time, in patients with early disease, all subscales improve in early followup up to 2 years. Therefore, the SF-36 may be a sensitive outcome measure in early disease in patients with SLE.

Metrics

2 Record Views
40 citations in Web of Science
45 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Rheumatology
Logo image